Short answer · Medically reviewed summary · Last updated: 2026-05-08
Kidney cancer, primarily known as renal cell carcinoma (RCC), was first formally characterized in the 19th century, with the pathologist Paul Grawitz proposing the influential "hypernephroma" theory in 1883. Over the past 140 years, our understanding has shifted from viewing kidney cancer as a single entity to recognizing it as a complex collection of distinct molecular subtypes, transforming it from a largely untreatable condition into one managed with precision medicine. When was kidney cancer first identified? While physicians in antiquity noted symptoms of hematuria (blood in the urine), the clinical definition of kidney cancer began in earnest during the 1800s.
What is the history of Kidney Cancer?
History of Kidney Cancer: when and how it was discovered, and the milestones in research since, medically reviewed.
Kidney cancer, primarily known as renal cell carcinoma (RCC), was first formally characterized in the 19th century, with the pathologist Paul Grawitz proposing the influential "hypernephroma" theory in 1883. Over the past 140 years, our understanding has shifted from viewing kidney cancer as a single entity to recognizing it as a complex collection of distinct molecular subtypes, transforming it from a largely untreatable condition into one managed with precision medicine.
When was kidney cancer first identified?
While physicians in antiquity noted symptoms of hematuria (blood in the urine), the clinical definition of kidney cancer began in earnest during the 1800s. In 1826, König described the first case of renal carcinoma, but it was Paul Grawitz in 1883 who famously misidentified these tumors as arising from adrenal remnants, terming them "hypernephromas." This historical misconception persisted for decades until subsequent histological studies confirmed that the vast majority of kidney cancer cases actually originate from the renal tubular epithelium.
How has the treatment of kidney cancer evolved?
The history of kidney cancer treatment is a transition from radical surgery to systemic biological therapy. Key milestones include:
- 1950s-1960s: The establishment of radical nephrectomy as the gold standard for localized kidney cancer.
- 1990s: The introduction of immunotherapy using cytokines (Interleukin-2 and Interferon-alpha), which provided the first durable responses in metastatic cases.
- 2005-Present: The era of targeted therapies (VEGF and mTOR inhibitors) and modern immune checkpoint inhibitors, which have significantly extended survival rates.
How has genetics transformed our understanding?
Modern genomics has fundamentally changed how we categorize kidney cancer. We now know that hereditary forms, such as von Hippel-Lindau (VHL) disease, account for approximately 2-4% of all cases. Identifying the VHL gene mutation in the 1990s provided a roadmap for understanding how kidney cancer cells manipulate oxygen-sensing pathways to grow, leading directly to the development of life-saving targeted drugs used by patients today.
Next steps
- Consult a urologic oncologist to discuss the specific histological subtype of your kidney cancer diagnosis.
- Connect with the 4 community members on DiseaseMaps.org to share experiences and coping strategies.
- Review clinical trial databases like ClinicalTrials.gov for the latest research on advanced kidney cancer therapies.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- National Cancer Institute (NCI) - Renal Cell Carcinoma Overview
- PubMed: "The History of Renal Cell Carcinoma" (Historical review articles)
- Orphanet: Rare diseases of the kidney
